Chun-Wei Lee1,2, Fu-Fei Tsai3, Min-I Su4, Hung-I Yeh1, Yi-Ting Chiang5, Chi-Feng Hsieh5, Chun-Yen Chen1. 1. Cardiovascular Division, Department of Internal Medicine, Mackay Memorial Hospital, Mackay Medical College, New Taipei City. 2. Department of Nursing, Mackay Junior College of Medicine, Nursing and Management, New Taipei City, Taiwan. 3. Department of Nursing, Tajen Univeristy, Yanpu Township, Pingtung County. 4. Cardiovascular Division, Department of Internal Medicine, Mackay Memorial Hospital, Taitung. 5. School of Medicine for International Students, I-Shou University, Kaohsiung.
Abstract
BACKGROUND: To investigate whether there is an increased risk of cardiovascular (CV) events in patients with diabetes associated with adding proton pump inhibitors (PPIs) to clopidogrel (CLO) therapy after bare-metal stent (BMS) deployment. METHODS: We used the National Health Insurance Research Database to conduct this retrospective cohort study. We enrolled 6,757 patients with diabetes who underwent BMS deployment and received CLO with/without PPIs for 90 days (6,243 in the CLO subgroup and 514 in the CLO plus PPI subgroup). The endpoints were acute coronary syndrome and re-admission for revascularization (PCI or coronary artery bypass graft surgery) after 3, 6, and 12 months. RESULTS: The patients who received CLO with PPIs had no significant increase in adverse CV events compared to those without PPIs within 1 year after BMS deployment [3-month hazard ratio (HR) = 0.87, 95% confidence interval (CI), 0.65-1.15; 6 months, HR = 0.95, 95% CI, 0.78-1.15; 1 year, HR = 0.60, 95% CI, 0.81-1.12]. CONCLUSIONS: In patients with diabetes undergoing BMS deployment, there was no evidence of an increased risk of CV events among concomitant users of CLO and PPIs. Our results indicate that the use of PPIs may not modify the protective effect of CLO after BMS implantation.
BACKGROUND: To investigate whether there is an increased risk of cardiovascular (CV) events in patients with diabetes associated with adding proton pump inhibitors (PPIs) to clopidogrel (CLO) therapy after bare-metal stent (BMS) deployment. METHODS: We used the National Health Insurance Research Database to conduct this retrospective cohort study. We enrolled 6,757 patients with diabetes who underwent BMS deployment and received CLO with/without PPIs for 90 days (6,243 in the CLO subgroup and 514 in the CLO plus PPI subgroup). The endpoints were acute coronary syndrome and re-admission for revascularization (PCI or coronary artery bypass graft surgery) after 3, 6, and 12 months. RESULTS: The patients who received CLO with PPIs had no significant increase in adverse CV events compared to those without PPIs within 1 year after BMS deployment [3-month hazard ratio (HR) = 0.87, 95% confidence interval (CI), 0.65-1.15; 6 months, HR = 0.95, 95% CI, 0.78-1.15; 1 year, HR = 0.60, 95% CI, 0.81-1.12]. CONCLUSIONS: In patients with diabetes undergoing BMS deployment, there was no evidence of an increased risk of CV events among concomitant users of CLO and PPIs. Our results indicate that the use of PPIs may not modify the protective effect of CLO after BMS implantation.
Entities:
Keywords:
Bare metal stent; Clopidogrel; Diabetes; Proton pump inhibitor
Authors: Subhash Banerjee; Rick A Weideman; Mark W Weideman; Bertis B Little; Kevin C Kelly; Jennifer T Gunter; Kathryn L Tortorice; Michelle Shank; Byron Cryer; Robert F Reilly; Sunil V Rao; Adnan Kastrati; James A de Lemos; Emmanouil S Brilakis; Deepak L Bhatt Journal: Am J Cardiol Date: 2011-01-19 Impact factor: 2.778
Authors: Stefan Agewall; M Cattaneo; J P Collet; F Andreotti; G Y H Lip; F W A Verheugt; K Huber; E L Grove; J Morais; S Husted; S Wassmann; G Rosano; D Atar; A Pathak; K Kjeldsen; R F Storey Journal: Eur Heart J Date: 2013-02-20 Impact factor: 29.983
Authors: P W Serruys; P de Jaegere; F Kiemeneij; C Macaya; W Rutsch; G Heyndrickx; H Emanuelsson; J Marco; V Legrand; P Materne Journal: N Engl J Med Date: 1994-08-25 Impact factor: 91.245
Authors: J Dawn Abbott; Matthew R Voss; Mamoo Nakamura; Howard A Cohen; Faith Selzer; Kevin E Kip; Helen A Vlachos; Robert L Wilensky; David O Williams Journal: J Am Coll Cardiol Date: 2007-11-20 Impact factor: 24.094
Authors: Donald E Cutlip; Manish S Chauhan; Donald S Baim; Kalon K L Ho; Jeffrey J Popma; Joseph P Carrozza; David J Cohen; Richard E Kuntz Journal: J Am Coll Cardiol Date: 2002-12-18 Impact factor: 24.094